By E. Janene Geiss
Philadelphia, Oct. 31 - AM-Pharma BV said Monday it raised €9 million in a series B financing round.
Inventages Venture Capital was the lead investor, committing €6 million and ABN-AMRO Life Sciences Capital committed €3 million, according to a company news release.
The company obtained an additional €2 million from a Dutch government research grant through SenterNovem in April 2005.
Company officials said the funding will be used to advance several of its development projects through phase II clinical trials.
"We are extremely excited about this investment, which will allow us to take our three lead compounds into the next clinical phase on their way to become safe and efficacious treatments, targeting large markets with a high medical need," Bruno Giannetti, president and chief executive of AM-Pharma, said in the release.
Research efforts are devoted to the development of new product candidates to treat fungal and bacterial infections, sepsis and ulcerative colon disease, officials said.
AM-Pharma is a biopharmaceutical company based in Bunnik, the Netherlands.
| Issuer: | AM-Pharma BV
|
| Issue: | Series B financing
|
| Amount: | €9 million
|
| Investors: | Inventages Venture Capital (lead), ABN-AMRO Life Sciences Capital
|
| Announcement date: | Oct. 31
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
